CN111902536B - 用于真核基因组修饰的改造的cas9系统 - Google Patents

用于真核基因组修饰的改造的cas9系统 Download PDF

Info

Publication number
CN111902536B
CN111902536B CN201980013625.2A CN201980013625A CN111902536B CN 111902536 B CN111902536 B CN 111902536B CN 201980013625 A CN201980013625 A CN 201980013625A CN 111902536 B CN111902536 B CN 111902536B
Authority
CN
China
Prior art keywords
sequence
cell
engineered
guide rna
cas9 protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201980013625.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN111902536A (zh
Inventor
T.西贝克
陈福强
G.戴维斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sigma-Aldrich Co LLC
Original Assignee
Sigma-Aldrich Co LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma-Aldrich Co LLC filed Critical Sigma-Aldrich Co LLC
Publication of CN111902536A publication Critical patent/CN111902536A/zh
Application granted granted Critical
Publication of CN111902536B publication Critical patent/CN111902536B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C12N9/222—Clustered regularly interspaced short palindromic repeats [CRISPR]-associated [CAS] enzymes
    • C12N9/226—Class 2 CAS enzyme complex, e.g. single CAS protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/85—Fusion polypeptide containing an RNA binding domain
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/21—Endodeoxyribonucleases producing 5'-phosphomonoesters (3.1.21)
    • C12Y301/21001—Deoxyribonuclease I (3.1.21.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
CN201980013625.2A 2018-02-15 2019-02-15 用于真核基因组修饰的改造的cas9系统 Active CN111902536B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862631304P 2018-02-15 2018-02-15
US62/631304 2018-02-15
US201862720525P 2018-08-21 2018-08-21
US62/720525 2018-08-21
PCT/US2019/018335 WO2019161290A1 (en) 2018-02-15 2019-02-15 Engineered cas9 systems for eukaryotic genome modification

Publications (2)

Publication Number Publication Date
CN111902536A CN111902536A (zh) 2020-11-06
CN111902536B true CN111902536B (zh) 2024-07-30

Family

ID=65995829

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980013625.2A Active CN111902536B (zh) 2018-02-15 2019-02-15 用于真核基因组修饰的改造的cas9系统

Country Status (11)

Country Link
US (2) US10767193B2 (cg-RX-API-DMAC7.html)
EP (1) EP3752607A1 (cg-RX-API-DMAC7.html)
JP (3) JP7109547B2 (cg-RX-API-DMAC7.html)
KR (3) KR102465067B1 (cg-RX-API-DMAC7.html)
CN (1) CN111902536B (cg-RX-API-DMAC7.html)
AU (3) AU2019222568B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020010479A2 (cg-RX-API-DMAC7.html)
CA (2) CA3281020A1 (cg-RX-API-DMAC7.html)
IL (2) IL321024A (cg-RX-API-DMAC7.html)
SG (1) SG11202007382TA (cg-RX-API-DMAC7.html)
WO (1) WO2019161290A1 (cg-RX-API-DMAC7.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3204496A1 (en) 2014-10-10 2017-08-16 Editas Medicine, Inc. Compositions and methods for promoting homology directed repair
US11111492B2 (en) * 2017-03-06 2021-09-07 Florida State University Research Foundation, Inc. Genome engineering methods using a cytosine-specific Cas9
CN112654710A (zh) 2018-05-16 2021-04-13 辛瑟高公司 用于指导rna设计和使用的方法和系统
AU2019291918B2 (en) 2018-06-29 2025-06-12 Editas Medicine, Inc. Synthetic guide molecules, compositions and methods relating thereto
US10913941B2 (en) 2019-02-14 2021-02-09 Metagenomi Ip Technologies, Llc Enzymes with RuvC domains
SG11202108812SA (en) 2019-02-15 2021-09-29 Sigma Aldrich Co Llc Crispr/cas fusion proteins and systems
EP4219700A1 (en) 2019-03-07 2023-08-02 The Regents of the University of California Crispr-cas effector polypeptides and methods of use thereof
JP7785002B2 (ja) 2019-11-05 2025-12-12 ペアーワイズ プランツ サービシズ, インコーポレイテッド 対立遺伝子のrnaにコードされたdnaの置換のための組成物および方法
KR20220116512A (ko) 2019-12-17 2022-08-23 시그마-알드리치 컴퍼니., 엘엘씨 박테로이데스의 게놈편집
GB2617659B (en) * 2020-02-14 2024-05-01 Metagenomi Inc Enzymes with RuvC domains
CA3177051A1 (en) * 2020-03-31 2021-10-07 Metagenomi, Inc. Class ii, type ii crispr systems
CN112159801B (zh) * 2020-07-13 2022-11-15 复旦大学 SlugCas9-HF蛋白、含有SlugCas9-HF蛋白的基因编辑系统及应用
KR102679001B1 (ko) * 2020-09-21 2024-06-28 고려대학교 산학협력단 신규의 개량된 염기 편집 또는 교정용 융합단백질 및 이의 용도
AU2021374974A1 (en) * 2020-11-06 2023-05-25 Pairwise Plants Services, Inc. Compositions and methods for rna-encoded dna-replacement of alleles
CN119452085A (zh) 2021-08-27 2025-02-14 宏基因组学公司 具有ruvc结构域的酶
CN113717960B (zh) * 2021-08-27 2023-07-18 电子科技大学 一种新Cas9蛋白、CRISPR-Cas9基因组定向编辑载体及基因组编辑方法
KR20240110603A (ko) 2021-11-24 2024-07-15 메타지노미, 인크. 엔도뉴클레아제 시스템
CN114657181B (zh) * 2022-04-01 2023-08-25 安徽大学 一种靶向H1.4的sgRNA以及H1.4基因编辑方法
EP4592322A4 (en) * 2022-09-23 2026-08-05 Chuang Woei Jer Fusion protein targeting alpha(IIB)beta3 integrin and containing a tissue plasminogen activator or a variant thereof, and its use

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015148863A2 (en) * 2014-03-26 2015-10-01 Editas Medicine, Inc. Crispr/cas-related methods and compositions for treating sickle cell disease

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030232430A1 (en) 2001-11-26 2003-12-18 Advanced Cell Technology Methods for making and using reprogrammed human somatic cell nuclei and autologous and isogenic human stem cells
ES2728782T3 (es) 2012-05-25 2019-10-28 Univ California Métodos y composiciones para la modificación de ADN objetivo dirigida por ARN y para la modulación de la transcripción dirigida por ARN
DK3363902T3 (da) 2012-12-06 2020-01-02 Sigma Aldrich Co Llc Crispr-baseret genommodifikation og -regulering
KR102955556B1 (ko) * 2012-12-12 2026-04-22 더 브로드 인스티튜트, 인코퍼레이티드 서열 조작을 위한 crispr-cas 성분 시스템, 방법 및 조성물
WO2014197748A2 (en) 2013-06-05 2014-12-11 Duke University Rna-guided gene editing and gene regulation
US9074199B1 (en) * 2013-11-19 2015-07-07 President And Fellows Of Harvard College Mutant Cas9 proteins
EP3097212A4 (en) * 2014-01-24 2017-10-04 North Carolina State University Methods and compositions for sequences guiding cas9 targeting
US10450584B2 (en) * 2014-08-28 2019-10-22 North Carolina State University Cas9 proteins and guiding features for DNA targeting and genome editing
EP3845655B1 (en) * 2014-10-01 2025-01-01 The General Hospital Corporation Methods for increasing efficiency of nuclease-induced homology-directed repair
DK3604527T3 (da) 2016-06-02 2021-05-31 Sigma Aldrich Co Llc Anvendelse af programmerbare dna-bindingsproteiner til at forbedre målrettet genommodifikation
CN109688820B (zh) 2016-06-24 2023-01-10 科罗拉多州立大学董事会(法人团体) 用于生成条形码化组合文库的方法
EP4650364A3 (en) 2016-07-06 2026-01-21 Vertex Pharmaceuticals Incorporated Materials and methods for treatment of pain related disorders
US11242513B2 (en) * 2016-12-14 2022-02-08 Wageningen Universiteit Thermostable Cas9 nucleases
KR102655021B1 (ko) * 2017-07-11 2024-04-04 시그마-알드리치 컴퍼니., 엘엘씨 표적된 게놈 변형을 개선하기 위한 뉴클레오솜 상호작용 단백질 도메인 사용
CA3071769A1 (en) 2017-07-31 2019-02-07 Reflection Biotechnologies Limited Cellular models of and therapies for ocular diseases

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015148863A2 (en) * 2014-03-26 2015-10-01 Editas Medicine, Inc. Crispr/cas-related methods and compositions for treating sickle cell disease

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Complete genome sequence of thermophilic Bacillus smithii type strain DSM 4216(T);Bosma, E. F. et al.;Standards in Genomic Sciences;第11卷(第52期);摘要 *
CRISPR-associated protein cas9/csn1, subtype II/nmemi [Bacillus smithii 7_3_47FAA];Earl, A. et al.;GenBank Database;ORIGIN部分 *

Also Published As

Publication number Publication date
AU2019222568B2 (en) 2021-10-14
AU2022200130A1 (en) 2022-02-10
EP3752607A1 (en) 2020-12-23
WO2019161290A1 (en) 2019-08-22
JP2024161376A (ja) 2024-11-19
KR20220015502A (ko) 2022-02-08
IL274528B2 (en) 2025-10-01
CA3084020A1 (en) 2019-08-22
JP7559005B2 (ja) 2024-10-01
KR102465067B1 (ko) 2022-11-10
IL274528B1 (en) 2025-06-01
US20200354752A1 (en) 2020-11-12
KR20200121342A (ko) 2020-10-23
JP2021505180A (ja) 2021-02-18
KR102684890B1 (ko) 2024-07-12
JP7109547B2 (ja) 2022-07-29
CA3084020C (en) 2025-11-25
JP2022122910A (ja) 2022-08-23
KR20230022258A (ko) 2023-02-14
SG11202007382TA (en) 2020-08-28
IL321024A (en) 2025-07-01
CN111902536A (zh) 2020-11-06
AU2024202158A1 (en) 2024-05-02
IL274528A (en) 2020-06-30
KR102494449B1 (ko) 2023-01-31
US20190249200A1 (en) 2019-08-15
AU2019222568A1 (en) 2020-05-21
AU2024202158B2 (en) 2026-07-30
US10767193B2 (en) 2020-09-08
US12297449B2 (en) 2025-05-13
AU2022200130B2 (en) 2024-03-07
CA3281020A1 (en) 2026-03-02
BR112020010479A2 (pt) 2020-11-24

Similar Documents

Publication Publication Date Title
JP7559005B2 (ja) 真核ゲノム修飾のための操作されたCas9システム
US12084675B2 (en) Using programmable DNA binding proteins to enhance targeted genome modification
JP2020530992A (ja) Crispr/casアクチベーターシステムのための合成ガイドrna
KR20230053732A (ko) 표적된 게놈 변형을 개선하기 위한 뉴클레오솜 상호작용 단백질 도메인 사용
US20230287377A1 (en) Crispr/cas fusion proteins and systems
AU2021236230A1 (en) High fidelity SpCas9 nucleases for genome modification
US20240409907A1 (en) Improved prime editing system efficiency with cis-acting regulatory elements
HK40040051B (en) Engineered cas9 systems for eukaryotic genome modification
HK40040051A (en) Engineered cas9 systems for eukaryotic genome modification
BR122025004697B1 (pt) Sistemas para modificar um genoma eucariótico, pluralidade de ácidos nucleicos, vetor, e proteína de fusão
BR122025004697A2 (pt) Sistema para modificar uma sequência cromossômica em uma célula eucariótica, pluralidade de ácidos nucleicos, vetor, célula eucariótica, proteína de fusão, composição e usos

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40040051

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant